Search

Your search keyword '"Ullmann, Andrew J"' showing total 17 results
Start Over Author "Ullmann, Andrew J" Journal annals of hematology
17 results on '"Ullmann, Andrew J"'

1. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

Author

Mellinghoff, Sibylle C., Panse, Jens, Alakel, Nael, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Kiehl, Michael, Koldehoff, Michael, Krause, Stefan W., Lehners, Nicola, von Lilienfeld-Toal, Marie, Löhnert, Annika Y., Maschmeyer, Georg, Teschner, Daniel, Ullmann, Andrew J., Penack, Olaf, Ruhnke, Markus, Mayer, Karin, Ostermann, Helmut, Wolf, Hans-H., and Cornely, Oliver A.

Published
2017
Full Text
View/download PDF

2. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016

Author

Ullmann, Andrew J., Schmidt-Hieber, Martin, Bertz, Hartmut, Heinz, Werner J., Kiehl, Michael, Krüger, William, Mousset, Sabine, Neuburger, Stefan, Neumann, Silke, Penack, Olaf, Silling, Gerda, Vehreschild, Jörg Janne, Einsele, Hermann, Maschmeyer, Georg, and on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)

Published
2016
Full Text
View/download PDF

3. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

Author

Tacke, Daniela, Buchheidt, Dieter, Karthaus, Meinolf, Krause, Stefan W., Maschmeyer, Georg, Neumann, Silke, Ostermann, Helmut, Penack, Olaf, Rieger, Christina, Ruhnke, Markus, Sandherr, Michael, Schweer, Katharina E., Ullmann, Andrew J., and Cornely, Oliver A.

Published
2014
Full Text
View/download PDF

4. Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Mousset, Sabine, Buchheidt, Dieter, Heinz, Werner, Ruhnke, Markus, Cornely, Oliver A., Egerer, Gerlinde, Krüger, William, Link, Hartmut, Neumann, Silke, Ostermann, Helmut, Panse, Jens, Penack, Olaf, Rieger, Christina, Schmidt-Hieber, Martin, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew J., Wolf, Hans-Heinrich, Maschmeyer, Georg, and Böhme, Angelika

Published
2014
Full Text
View/download PDF

5. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Weissinger, Florian, Auner, Holger W., Bertz, Hartmut, Buchheidt, Dieter, Cornely, Oliver A., Egerer, Gerlinde, Heinz, Werner, Karthaus, Meinolf, Kiehl, Michael, Krüger, William, Penack, Olaf, Reuter, Stefan, Ruhnke, Markus, Sandherr, Michael, Salwender, Hans-Jürgen, Ullmann, Andrew J., Waldschmidt, Dirk T., and Wolf, Hans H.

Published
2012
Full Text
View/download PDF

6. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Böhme, Angelika, Ruhnke, Markus, Buchheidt, Dieter, Cornely, Oliver A., Einsele, Herrmann, Enzensberger, Ruxandra, Hebart, Holger, Heinz, Werner, Junghanss, Christian, Karthaus, Meinolf, Krüger, William, Krug, Utz, Kubin, Thomas, Penack, Olaf, Reichert, Dietmar, Reuter, Stefan, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew J., and Maschmeyer, Georg

Published
2009
Full Text
View/download PDF

9. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Einsele, Hermann, Bertz, Hartmut, Beyer, Jörg, Kiehl, Michael G., Runde, Volker, Kolb, Hans-Jochen, Holler, Ernst, Beck, Robert, Schwerdfeger, Rainer, Schumacher, Ulrike, Hebart, Holger, Martin, Hans, Kienast, Joachim, Ullmann, Andrew J., Maschmeyer, Georg, Krüger, William, Niederwieser, Dietger, Link, Hartmut, Schmidt, Christian A., Oettle, Helmut, and Klingebiel, Thomas

Published
2003
Full Text
View/download PDF

10. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Cornely, Oliver A., Böhme, Angelika, Buchheidt, Dieter, Glasmacher, Axel, Kahl, Christoph, Karthaus, Meinolf, Kern, Winfried, Krüger, William, Maschmeyer, Georg, Ritter, Jörg, Salwender, Hans J., Sandherr, Michael, Schiel, Xaver, Schüttrumpf, Silke, Sieniawski, Michal, Silling, Gerda, Ullmann, Andrew J., and Wolf, Hans-Heinrich

Published
2003
Full Text
View/download PDF

11. Treatment of fungal infections in hematology and oncology

Author

Böhme, Angelika, Ruhnke, Markus, Buchheidt, Dieter, Karthaus, Meinolf, Einsele, Hermann, Guth, Stefan, Heussel, Gudrun, Heussel, Claus-Peter, Junghanss, Christian, Kern, Winfried K., Kubin, Thomas, Maschmeyer, Georg, Sezer, Orhan, Silling, Gerda, Südhoff, Thomas, Szelényi, Hubert, and Ullmann, Andrew J.

Published
2003
Full Text
View/download PDF

12. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Author

Mellinghoff, Sibylle C., Panse, Jens, Alakel, Nael, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Kiehl, Michael, Koldehoff, Michael, Krause, Stefan W., Lehners, Nicola, von Lilienfeld-Toal, Marie, Löhnert, Annika Y., Maschmeyer, Georg, Teschner, Daniel, Ullmann, Andrew J., Penack, Olaf, Ruhnke, Markus, Mayer, Karin, and Ostermann, Helmut

Subjects
HEMATOLOGIC malignancies, COMMUNICABLE disease treatment, MYCOSES, ANTIFUNGAL agents, IMMUNOCOMPROMISED patients, AMPHOTERICIN B, NEUTROPENIA, ONCOLOGY, PATIENTS, PREVENTION, THERAPEUTICS, SOCIETIES, ACUTE myeloid leukemia treatment, MYELODYSPLASTIC syndromes treatment, HETEROCYCLIC compounds, VORICONAZOLE, CLINICAL trials, DRUG monitoring, HEMATOLOGY, HEMATOPOIETIC stem cell transplantation, MEDICAL societies, MYELODYSPLASTIC syndromes, PREVENTIVE health services, ACUTE myeloid leukemia
Abstract

Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). Despite substantial risk of IFI, we cannot provide a stronger recommendation for these patients. There is poor evidence regarding voriconazole prophylaxis in patients with neutropenia (CII). Therapeutic drug monitoring TDM should be performed within 2 to 5 days of initiating voriconazole prophylaxis and should be repeated in case of suspicious adverse events or of dose changes of interacting drugs (BIItu). General TDM during posaconazole prophylaxis is not recommended (CIItu), but may be helpful in cases of clinical failure such as breakthrough IFI for verification of compliance or absorption. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

13. Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Mousset, Sabine, primary, Buchheidt, Dieter, additional, Heinz, Werner, additional, Ruhnke, Markus, additional, Cornely, Oliver A., additional, Egerer, Gerlinde, additional, Krüger, William, additional, Link, Hartmut, additional, Neumann, Silke, additional, Ostermann, Helmut, additional, Panse, Jens, additional, Penack, Olaf, additional, Rieger, Christina, additional, Schmidt-Hieber, Martin, additional, Silling, Gerda, additional, Südhoff, Thomas, additional, Ullmann, Andrew J., additional, Wolf, Hans-Heinrich, additional, Maschmeyer, Georg, additional, and Böhme, Angelika, additional

Published
2013
Full Text
View/download PDF

14. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Böhme, Angelika, primary, Ruhnke, Markus, additional, Buchheidt, Dieter, additional, Cornely, Oliver A., additional, Einsele, Herrmann, additional, Enzensberger, Ruxandra, additional, Hebart, Holger, additional, Heinz, Werner, additional, Junghanss, Christian, additional, Karthaus, Meinolf, additional, Krüger, William, additional, Krug, Utz, additional, Kubin, Thomas, additional, Penack, Olaf, additional, Reichert, Dietmar, additional, Reuter, Stefan, additional, Silling, Gerda, additional, Südhoff, Thomas, additional, Ullmann, Andrew J., additional, and Maschmeyer, Georg, additional

Published
2008
Full Text
View/download PDF

16. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and ?106/kg T cells may have an adverse effect on transplant-related mortality

Author

Hartwig, Udo F., primary, Winkelmann, Nils, additional, Wehler, Thomas, additional, Kreiter, Sebastian, additional, Schneider, Peter M., additional, Meyer, Ralf G., additional, Ullmann, Andrew J., additional, Huber, Christoph, additional, Kolbe, Karin, additional, and Herr, Wolfgang, additional

Published
2005
Full Text
View/download PDF

17. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and =106/kg T cells may have an adverse effect on transplant-related mortality.

Author

Hartwig, Udo F., Winkelmann, Nils, Wehler, Thomas, Kreiter, Sebastian, Schneider, Peter M., Meyer, Ralf G., Ullmann, Andrew J., Huber, Christoph, Kolbe, Karin, and Herr, Wolfgang

Subjects
HOMOGRAFTS, CELL transplantation, STEM cells, T cells, IMMUNITY, CD antigens, GLOBULINS
Abstract

In patients undergoing allogeneic peripheral blood stem cell (PBSC) transplantation after reduced-intensity conditioning (RIC), graft-versus-host disease (GVHD) represents a major cause of morbidity and mortality. T-cell depletion (TCD) prevents GVHD but carries potential risks of graft failure, opportunistic infections, and disease relapse. We explored ex vivo TCD of stem cell allografts that were administered after RIC treatment. Thirteen high-risk patients with hematological malignancies were treated with a fludarabine/melphalan-based RIC regimen followed by transplantation of immunomagnetically selected CD34+ PBSC from HLA-identical sibling or matched unrelated donors. Patients were sequentially enrolled in two cohorts: group A (n=6) received antithymocyte globulin (ATG) during conditioning and 105 donor T cells/kg at transplantation, while group B (n=7) received 106 donor T cells/kg without ATG pretreatment. Primary graft failure occurred in two patients of group A and in one patient of group B. Complete donor chimerism persisting more than 1 year was achieved in two cases per cohort. Acute grade II to IV or chronic extensive GVHD were observed in a total of six patients (group A, 2; group B, 4). Procedure-related deaths were mainly due to severe pneumonia occurring in two patients of group A and in five patients of group B. These results suggest that CD34 selection of reduced-intensity PBSC allografts may cause adverse effects upon specific antimicrobial immunity which can lead to fatal infections, particularly in high-risk patients. In our study, simultaneous add-back of =106/kg donor T cells was unable to compensate for this deficiency. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results